Report topline data from the XEN1101 Phase 2b X-TOLE clinical trial
Delivered after the deadline (4 days after the deadline)
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 14 Jan 2021
- Due
- 30 Sep 2021
- Delivered
- 4 Oct 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“topline data anticipated in the third quarter of 2021”
What we found
Evidence strength A What the grades mean
The company announced the topline data on October 4, 2021, which occurred after the third quarter of 2021 deadline.
-
A Xenon Pharmaceuticals Inc. 8-K filed 2021-10-04
“BURNABY, British Columbia, October 4, 2021 – Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today reported positive topline results from the Phase 2b X-TOLE clinical trial” ✓ confirmed on the page
Checked 25 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout
- Indicative materiality
- Medium rules
- Action
- Report
- Deliverable
- XEN1101 Phase 2b X-TOLE topline data
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
- Conditional
- Yes: dependent upon ongoing patient enrollment rates
- Depends on
- Customer
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Xenon Pharmaceuticals Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-XENE-022085 · Corrections policy